Ms. Donley brings a unique combination of business and legal experience to Stemina. She has more than a dozen years of experience in intellectual property, law and business management. Ms. Donley served as General Counsel and Director of Business Development for WARF for more than eight years. During those eight years, Ms. Donley negotiated hundreds of licenses, sponsored research and collaboration agreements between industry and WARF, the intellectual property management organization for the University of Wisconsin.

Gabriela Cezar is a faculty member at the University of Wisconsin—Madison where she pioneered the application of metabolomics to stem cell biology. Her research involves human embryonic stem (hES) cells, cancer stem cells and cells derived from hES cells such as neurons, cardiomyocytes and hepatocyte-like cells. In addition, Dr. Cezar heads the Stem Cell Safety Sciences Lab at UW and is a scientific collaborator with WiCell Research Institute.

Mr. Ferrara began his career with Eli Lilly & Company. In the course of his twenty-year tenure with Lilly, he served in a number of business areas in the United States and Europe. During his last four years at Eli Lilly, he was Corporate Director of New Product Planning and Licensing. His line management experience included the management of pharmaceutical operations, including all aspects of marketing and sales, for both Lilly and Dista in France and a member of the Board of Lilly Industries in the United Kingdom. In May, 1984, Mr. Ferrara co-found Polygen Corporation, a computer software company serving the chemical and pharmaceutical research industries, and initiated a number of research and licensing agreements with academic institutions and major health care corporations in the United States, Europe and Japan. Since founding Boston Healthcare in 1993, he has been involved in the development of a number of companies. Presently he serves on the Boards of Sucampo Pharmaceuticals and Indevus Pharmaceuticals, Inc., both publicly traded companies, and also VelQuest Corporation. In addition, Mr. Ferrara serves on the Board of the Pierce Law Center and is a Member of the Corporation of the Woods Hole Oceanographic Institution. Mr. Ferrara has been a guest speaker at numerous professional meetings and conferences.

Laura Francis leads the finance organization for Promega Corporation, a Madison-based firm which supplies solutions and technical support to the life sciences industry and has revenues exceeding $200 million. She is responsible for planning, analysis, business intelligence and business development for the company. Since Ms. Francis joined Promega in 2004 the company has experienced 40% growth in revenue, 60% growth in profitability, and 85% growth in shareholder value. Ms. Francis was the key driver in three acquisitions that have added to organic revenue growth and profitability.

Prior to joining Genzyme in October, 1999, Dr. Marquis spent 5 years in drug discovery and development at Hybridon, Inc., and 2 years organizing a new department of preclinical development at Procept, Inc., both in Cambridge, Massachusetts. Her research background is primarily neurotoxicology and neurochemistry. Her responsibilities in recent years have included oversight of all areas of drug development work relating to toxicology and pharmacokinetics, experimental pharmacology, analytical chemistry, formulation and process development. From 1989 to 1994, Judy was Director of the Life Sciences Section of Arthur D. Little, Inc. with responsibilities for contract R & D and management consulting in pharmaceutical development and regulatory affairs. Prior to joining the pharmaceutical industry, she held academic positions at Harvard School of Public Health, Boston University School of Medicine, and Tufts University Medical School, and she has authored more than 80 peer-reviewed scientific publications. Judy is a former secretary of the American College of Toxicology, has been active in the Society of Toxicology and the Drug Information Agency and is also a Past-President of the American Board of Toxicology.

Andrew Morgan is the Vice President of Quality Operations and Site Manager for Genzyme Corporation’s Middleton, Wisconsin office. He is responsible for the oversight of all product quality control, quality assurance, and compliance activities. He works closely with Genzyme’s Research and Development division to develop an overall drug development quality and regulatory strategy. Mr. Morgan received his pharmacy degree from SWOSU School of Pharmacy in Weatherford, OK. Prior to joining Genzyme he served as the VP of Regulatory, Quality, and Pharmaceutical Sciences at Bone Care International in Middleton, Wisconsin and as the Director of Regulatory Affairs for Celltech Pharmaceuticals, Inc. in Rochester, New York.

Thomas M. Shannon was most recently Prodesse's Chief Executive Officer. Mr. Shannon assumed the position of CEO and board member of the biotech company in May 2002 and recently exited the company after its sale to Gen-Probe, Inc in November of 2009 for a purchase price of $87 million, including expected milestones. He currently is involved with his co-investors in the start up funding of Oshkosh Nanotechnology and Proxim Diagnostics Irvine, California. Other boards he serves on include Promentis Pharmaceuticals, and BizStarts Wisconsin. In 1996, he founded Shamrock Partners, the lead investment group in Prodesse's initial funding in 2002. From 1997-1999 he acquired and was CEO of three regional transportation companies in Nebraska and Florida, selling his majority interest in 2001. Prior to that Mr. Shannon held a variety of senior level management positions in sales and general management as a registered principal for Equitable and its subsidiaries, including Alliance Capital and Donaldson, Lufkin and Jenrette. Earlier in his career, Mr. Shannon founded and was President of Shannon Financial Associates, Inc. He holds a Finance degree from the University of Wisconsin and earned the Certified Financial Planner (CFP) and Chartered Financial Consultant (CHFC) credentials.